PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Works by Ji-youn Han
Results: 86
1
2
Olmutinib in T790M-positive non-small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study.
- Published in:
- 2021
- By:
- Publication type:
- journal article
3
Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer.
- Published in:
- 2008
- By:
- Publication type:
- journal article
4
Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first-line chemotherapy with second-line crossover in patients with advanced nonsmall cell lung cancer.
- Published in:
- 2008
- By:
- Publication type:
- journal article
5
TARGET: A Phase II, Open-Label, Single-Arm Study of 5-Year Adjuvant Osimertinib in Completely Resected EGFR-Mutated Stage II to HIB NSCLC Post Complete Surgical Resection.
- Published in:
- Clinical Lung Cancer, 2024, v. 25, n. 1, p. 80, doi. 10.1016/j.cllc.2023.09.005
- By:
- Publication type:
- Article
6
Improved Survival Outcomes in Patients With MET Dysregulated Advanced NSCLC Treated With MET Inhibitors: Results of a Multinational Retrospective Chart Review.
- Published in:
- Clinical Lung Cancer, 2023, v. 24, n. 7, p. 641, doi. 10.1016/j.cllc.2023.08.011
- By:
- Publication type:
- Article
7
New subtraction algorithms for evaluation of lesions on dynamic contrast-enhanced MR mammography.
- Published in:
- 2002
- By:
- Publication type:
- journal article
8
A phase II trial of modified weekly irinotecan and cisplatin for chemotherapy-naïve patients with metastatic or recurrent squamous cell carcinoma of the esophagus.
- Published in:
- 2008
- By:
- Publication type:
- journal article
9
A phase II trial of modified weekly irinotecan and cisplatin for chemotherapy-naïve patients with metastatic or recurrent squamous cell carcinoma of the esophagus.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2008, v. 61, n. 1, p. 83, doi. 10.1007/s00280-007-0450-7
- By:
- Publication type:
- Article
10
Tumor Microenvironment Modulation by Neoadjuvant Erlotinib Therapy and Its Clinical Impact on Operable EGFR-Mutant Non-Small Cell Lung Cancer.
- Published in:
- Cancer Research & Treatment, 2024, v. 56, n. 1, p. 70, doi. 10.4143/crt.2023.482
- By:
- Publication type:
- Article
11
A Randomized Phase II Study of Irinotecan Plus Cisplatin with or without Simvastatin in Ever-Smokers with Extended Disease Small Cell Lung Cancer.
- Published in:
- Cancer Research & Treatment, 2023, v. 55, n. 3, p. 885, doi. 10.4143/crt.2023.283
- By:
- Publication type:
- Article
12
The Clinical Impact of Capmatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification.
- Published in:
- Cancer Research & Treatment, 2021, v. 53, n. 4, p. 1024, doi. 10.4143/crt.2020.1331
- By:
- Publication type:
- Article
13
Phase II Study of Pemetrexed as a Salvage Chemotherapy for Thymidylate Synthase-Low Squamous Cell Lung Cancer.
- Published in:
- Cancer Research & Treatment, 2021, v. 53, n. 1, p. 87, doi. 10.4143/crt.2020.741
- By:
- Publication type:
- Article
14
Sequential Treatment with an Immune Checkpoint Inhibitor Followed by a Small-Molecule Targeted Agent Increases Drug-Induced Pneumonitis.
- Published in:
- Cancer Research & Treatment, 2021, v. 53, n. 1, p. 77, doi. 10.4143/crt.2020.543
- By:
- Publication type:
- Article
15
Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies.
- Published in:
- Cancer Research & Treatment, 2020, v. 52, n. 1, p. 284, doi. 10.4143/crt.2019.200
- By:
- Publication type:
- Article
16
Incorporating Erlotinib or Irinotecan Plus Cisplatin into Chemoradiotherapy for Stage III Non-small Cell Lung Cancer According to EGFR Mutation Status.
- Published in:
- Cancer Research & Treatment, 2017, v. 49, n. 4, p. 981, doi. 10.4143/crt.2016.522
- By:
- Publication type:
- Article
17
Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer.
- Published in:
- Cancer Research & Treatment, 2017, v. 49, n. 4, p. 1001, doi. 10.4143/crt.2016.546
- By:
- Publication type:
- Article
18
A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR-Tyrosine Kinase Inhibitors.
- Published in:
- Cancer Research & Treatment, 2017, v. 49, n. 1, p. 10, doi. 10.4143/crt.2016.058
- By:
- Publication type:
- Article
19
A Phase II Study of Weekly Paclitaxel Plus Gemcitabine as a Second-Line Therapy in Patients with Metastatic or Recurrent Small Cell Lung Cancer.
- Published in:
- Cancer Research & Treatment, 2016, v. 48, n. 2, p. 465, doi. 10.4143/crt.2015.061
- By:
- Publication type:
- Article
20
A Phase II Trial of Docetaxel Plus Capecitabine in Patients with Previously Treated Non-Small Cell Lung Cancer.
- Published in:
- Japanese Journal of Clinical Oncology, 2006, v. 36, n. 12, p. 761, doi. 10.1093/jjco/hyl106
- By:
- Publication type:
- Article
21
A Phase II Study of a Daily x 4 Schedule of Vinorelbine Plus Cisplatin for Advanced Non-small Cell Lung Cancer.
- Published in:
- Japanese Journal of Clinical Oncology, 2000, v. 30, n. 10
- By:
- Publication type:
- Article
22
Drug Response of Patient-Derived Lung Cancer Cells Predicts Clinical Outcomes of Targeted Therapy.
- Published in:
- Cancers, 2024, v. 16, n. 4, p. 778, doi. 10.3390/cancers16040778
- By:
- Publication type:
- Article
23
Nivolumab after Induction Chemotherapy in Previously Treated Non-Small-Cell Lung Cancer Patients with Low PD-L1 Expression.
- Published in:
- Cancers, 2023, v. 15, n. 18, p. 4460, doi. 10.3390/cancers15184460
- By:
- Publication type:
- Article
24
Molecular Subtypes and Tumor Microenvironment Characteristics of Small-Cell Lung Cancer Associated with Platinum-Resistance.
- Published in:
- Cancers, 2023, v. 15, n. 14, p. 3568, doi. 10.3390/cancers15143568
- By:
- Publication type:
- Article
25
Early On-Treatment Prediction of the Mechanisms of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors.
- Published in:
- Cancers, 2022, v. 14, n. 6, p. 1512, doi. 10.3390/cancers14061512
- By:
- Publication type:
- Article
26
Cancer Patients' Willingness to Take COVID-19 Vaccination: A Nationwide Multicenter Survey in Korea.
- Published in:
- Cancers, 2021, v. 13, n. 15, p. 3883, doi. 10.3390/cancers13153883
- By:
- Publication type:
- Article
27
Patient-derived cell-based pharmacogenomic assessment to unveil underlying resistance mechanisms and novel therapeutics for advanced lung cancer.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2023, v. 42, n. 1, p. 1, doi. 10.1186/s13046-023-02606-3
- By:
- Publication type:
- Article
28
The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy.
- Published in:
- Radiation Oncology, 2014, v. 9, n. 1, p. 337, doi. 10.1186/s13014-014-0283-6
- By:
- Publication type:
- Article
29
Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION.
- Published in:
- British Journal of Cancer, 2024, v. 130, n. 10, p. 1679, doi. 10.1038/s41416-024-02615-9
- By:
- Publication type:
- Article
30
Single targeting of MET in EGFR-mutated and MET-amplified non-small cell lung cancer.
- Published in:
- British Journal of Cancer, 2023, v. 128, n. 12, p. 2186, doi. 10.1038/s41416-023-02264-4
- By:
- Publication type:
- Article
31
Impact of EGFR tyrosine kinase inhibitors versus chemotherapy on the development of leptomeningeal metastasis in never smokers with advanced adenocarcinoma of the lung.
- Published in:
- Journal of Neuro-Oncology, 2013, v. 115, n. 1, p. 95, doi. 10.1007/s11060-013-1199-y
- By:
- Publication type:
- Article
32
Simvastatin enhances irinotecan-induced apoptosis in human non-small cell lung cancer cells by inhibition of proteasome activity.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 5, p. 883, doi. 10.1007/s10637-010-9439-x
- By:
- Publication type:
- Article
33
Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 6, p. 791, doi. 10.1007/s10637-009-9319-4
- By:
- Publication type:
- Article
34
Somatic mutations of EGFR, ERBB2, ERBB3 and ERBB4 in juxtamembrane activating domains are rare in non-small cell lung cancers.
- Published in:
- 2010
- By:
- Publication type:
- Letter
35
The indirect effect of peer problems on adolescent depression through nucleus accumbens volume alteration.
- Published in:
- Scientific Reports, 2020, v. 10, n. 1, p. 1, doi. 10.1038/s41598-020-69769-3
- By:
- Publication type:
- Article
36
Prognostic implications of genetic variants in advanced non-small cell lung cancer: a genome-wide association study.
- Published in:
- Carcinogenesis, 2013, v. 34, n. 2, p. 307, doi. 10.1093/carcin/bgs356
- By:
- Publication type:
- Article
37
Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin.
- Published in:
- Journal of Pathology, 2010, v. 220, n. 4, p. 446, doi. 10.1002/path.2653
- By:
- Publication type:
- Article
38
Updated overall survival and ctDNA analysis in patients with EGFR T790M-positive advanced non-small cell lung cancer treated with lazertinib in the phase 1/2 LASER201 study.
- Published in:
- BMC Medicine, 2024, v. 22, n. 1, p. 1, doi. 10.1186/s12916-024-03620-8
- By:
- Publication type:
- Article
39
Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer.
- Published in:
- Oncogene, 1999, v. 18, n. 25, p. 3754, doi. 10.1038/sj.onc.1202769
- By:
- Publication type:
- Article
40
Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer.
- Published in:
- 2005
- By:
- Publication type:
- journal article
41
Hypoxia-inducible Factor 1α and Antiangiogenic Activity of Farnesyltransferase Inhibitor SCH66336 in Human Aerodigestive Tract Cancer.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2005, v. 97, n. 17, p. 1272, doi. 10.1093/jnci/dji251
- By:
- Publication type:
- Article
42
A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer.
- Published in:
- Clinical Lung Cancer, 2021, v. 22, n. 6, p. 531, doi. 10.1016/j.cllc.2021.04.005
- By:
- Publication type:
- Article
43
First-iGAP: A Randomized Placebo-Controlled Phase II Study of First-line Intercalated Gefitinib and Pemetrexed-Cisplatin Chemotherapy for Never-Smoker Lung Adenocarcinoma Patients.
- Published in:
- 2020
- By:
- Publication type:
- journal article
44
Effect of Accurate Staging Using Positron Emission Tomography on the Outcomes of Prophylactic Cranial Irradiation in Patients With Limited Stage Small-Cell Lung Cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
45
Clinical Significance of Heterogeneity in Response to Retreatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Lung Cancer Acquiring Secondary Resistance to the Drug.
- Published in:
- Clinical Lung Cancer, 2014, v. 15, n. 2, p. 145, doi. 10.1016/j.cllc.2013.11.008
- By:
- Publication type:
- Article
46
Prognostic Value of Gross Tumor Volume for Definitive Radiation Therapy in Patients With Locoregionally Recurrent Non-Small-Cell Lung Cancer After Surgical Resection.
- Published in:
- Clinical Lung Cancer, 2013, v. 14, n. 4, p. 399, doi. 10.1016/j.cllc.2012.11.002
- By:
- Publication type:
- Article
47
A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non–small cell lung cancer with EGFR mutation.
- Published in:
- Cancer (0008543X), 2023, v. 129, n. 3, p. 405, doi. 10.1002/cncr.34553
- By:
- Publication type:
- Article
48
Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer.
- Published in:
- 2020
- By:
- Publication type:
- journal article
49
Clinical outcome according to the level of preexisting epidermal growth factor receptor T790M mutation in patients with lung cancer harboring sensitive epidermal growth factor receptor mutations.
- Published in:
- Cancer (0008543X), 2014, v. 120, n. 14, p. 2090, doi. 10.1002/cncr.28711
- By:
- Publication type:
- Article
50
Direct isolation and characterization of circulating exosomes from biological samples using magnetic nanowires.
- Published in:
- Journal of Nanobiotechnology, 2019, v. 17, n. 1, p. N.PAG, doi. 10.1186/s12951-018-0433-3
- By:
- Publication type:
- Article